December 01, 2010 09:04 ET

Independent Testing of CDEX's Improved ID2 Meth Scanner for Commercial and Home Inspection Surpasses State and National Standards

TUCSON, AZ--(Marketwire - December 1, 2010) - CDEX Inc. (OTCBB: CEXI) (, a leading developer of chemical detection products, using patented technologies, for use in healthcare and security markets, announced the positive results of a field test study of its improved ID2 Meth Scanner used for commercial and home property inspection. The new version of ID2 Meth Scanner has been recalibrated for precision measuring and convenient operation. Capabilities of the improved ID2 Meth Scanner meet or exceed state and national requirements, including the state of California health-based risk standards of 1.5 ug/100cm2 detected. 

Independent testing was conducted by AZ Meth Detection Service™ at six randomly selected vacant HUD homes located in the Phoenix and Tucson, Arizona area. Initial mining samples were performed on 20 surface areas in each property as a base indicator to determine if meth residue was present. The improved ID2 Meth Scanner detected the presence of hazardous methamphetamine residue at higher levels than California's reference dose (RfD) legal standard of 1.5 micrograms/100 cm2 area, and the levels measured are considered potentially toxic at five of the six properties. AZ Meth Detection Service's ID2 assessment results were confirmed using a laboratory spectrometer. The cost of testing for surface meth residue with the ID2 Meth scanner is a fraction the cost of other technologies available and the results are real-time. The chemical swab tests currently in use are readable for only 45 to 90 seconds and this testing method destroys the meth residue itself in the process. The ID2 swabbed tests are readable instantly and samples may be stored for future reference for years if necessary, and the ID2 measuring process provides very high accuracy at locating hazardous meth residue.

Jeff Brumfield, CEO and Chairman of the Board of CDEX Inc., commented, "We believe our Improved ID2 Meth Scanner is the most reliable and cost effective testing device for determining toxic levels of Meth residue in the commercial and home Inspection markets. The team at AZ Meth Detection conducted the blind test on randomly selected HUD homes to establish a base and verify the accuracy of testing for surface meth residue with the improved ID2 and results were very impressive. We are launching the ID2 Meth Scanner in December 2010 and initial requests for purchasing the product have been very encouraging. Our research and development team continues to develop and enhance our proprietary technologies to serve the needs of our target markets in security and healthcare, while providing future growth opportunities in other markets where our detection applications will be deployed."

About CDEX
CDEX develops, manufactures and globally distributes products to the healthcare and security markets. The ValiMed product line provides life-saving validation of high-risk medications and returned narcotics. The ID2™ product line detects trace amounts of illegal drugs, such as methamphetamine. CDEX expects to advance its patented technologies to serve additional markets in the future where its proprietary products can be launched. To learn more about CDEX please visit

Non-historical statements are forward-looking, as defined in federal securities laws, and generally can be identified by words such as "expects," "plans," "may," "believes," "should," "intends," and similar words. These statements pose risks that cannot be accurately predicted. Consequently, results may differ materially from those expressed or implied. Such risks and uncertainties include, without limitation, the effectiveness, profitability and marketability of products, the protection of intellectual property and proprietary information, and other risks detailed periodically in filings with the SEC. There is no obligation to update any forward-looking statements.

Contact Information